Longevity Research

{
  "result": " **Executive Summary**\n\nThis tick established an analytical scaffold to test whether mTORC1–autophagy modulation causally suppresses the inflammaging biomarkers IL-6 and GDF-15 in diverse human populations. Because the knowledge base contained 122 entities but zero causal relations, the swarm focused on three converging lines of inquiry: (1) multi-ancestry proteogenetic colocalization of mTOR/autophagy protein QTLs (near *TSC2*, *RPTOR*, *ULK1*, and *ATG5*) with circulating IL-6 and GDF-15 genome-wide association signals across European, East Asian, and African cohorts; (2) de novo parameterization of rapamycin and everolimus dose-response matrices in ancestry-diverse human iPSC-derived macrophages, measuring autophagy flux markers and secreted cytokines; and (3) structured extraction protocols to link drug exposure metrics from solid-organ transplant and tuberous sclerosis trials to longitudinal IL-6 and GDF-15 trajectories. No primary causal findings were extracted this cycle, though four hypotheses were refined.\n\nThe intervention at the center of this framework is mTORC1 inhibition by rapamycin (sirolimus) and everolimus. In accessible terms, mTORC1 functions as a cellular nutrient sensor that, when chronically active, can block autophagy—the cellular recycling program that clears damaged proteins and organelles. The working hypothesis is that partial inhibition of mTORC1 restores autophagic flux, which in turn dampens the secretion of inflammatory and stress signals such as IL-6 and GDF-15. If this dose-resolvable link holds across genetic ancestries, it could anchor a pharmacological strategy to mitigate systemic inflammaging. It must be stressed, however, that this mechanism remains a directed hypothesis; the causal arrows and effect sizes in humans are exactly what the current triangulation effort seeks to establish.\n\nEvidence strength for the mTORC1–autophagy–IL-6/GDF-15 axis in our current graph is effectively absent. This tick produced zero new findings and zero relations, with the knowledge base still populated primarily by background and review literature rather than primary causal data. No human clinical, animal, or in vitro causal edges were validated during this cycle. While the genetic instruments, cellular assays, and clinical trial extraction frames have been scoped and parameterized, they have not yet yielded quantified causal links. Therefore, any inference that rapamycin reduces inflammaging through this specific pathway remains unproven within this knowledge base.\n\nOutstanding questions for the next tick center on execution and validation. Can multi-ancestry colocalization detect shared causal variants between mTOR/autophagy pQTLs and IL-6/GDF-15 GWAS signals, and do effect sizes differ by ancestry? Will the iPSC-macrophage experiments generate consistent EC50/Emax surfaces showing that autophagy flux predicts cytokine suppression across drug concentrations and durations? And do published transplant and TSC trials contain sufficient longitudinal biomarker density to serve as a human dose-response validation layer? The mission will continue to deprioritize unrelated aging hallmarks and non-human animal studies until at least one edge in this axis achieves human validation.\n\nOverall confidence in the scientific direction is cautiously hopeful but necessarily tempered. The mTOR pathway is a biologically plausible geroscience target, yet the mission has not extracted a single human-provenance causal relation for this axis. The triangulation strategy is methodologically sound, but the project remains at the starting line, with the next ticks determining whether these parameterized frames yield actionable, ancestry-aware causal edges.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}